EP2847175A4 - Compositions and methods for suppression of carbonic anhydrase activity - Google Patents

Compositions and methods for suppression of carbonic anhydrase activity

Info

Publication number
EP2847175A4
EP2847175A4 EP13787577.9A EP13787577A EP2847175A4 EP 2847175 A4 EP2847175 A4 EP 2847175A4 EP 13787577 A EP13787577 A EP 13787577A EP 2847175 A4 EP2847175 A4 EP 2847175A4
Authority
EP
European Patent Office
Prior art keywords
suppression
compositions
methods
carbonic anhydrase
anhydrase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13787577.9A
Other languages
German (de)
French (fr)
Other versions
EP2847175A1 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of EP2847175A1 publication Critical patent/EP2847175A1/en
Publication of EP2847175A4 publication Critical patent/EP2847175A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
EP13787577.9A 2012-05-08 2013-02-03 Compositions and methods for suppression of carbonic anhydrase activity Withdrawn EP2847175A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1810CH2012 2012-05-08
PCT/IB2013/050899 WO2013167994A1 (en) 2012-05-08 2013-02-03 Compositions and methods for suppression of carbonic anhydrase activity

Publications (2)

Publication Number Publication Date
EP2847175A1 EP2847175A1 (en) 2015-03-18
EP2847175A4 true EP2847175A4 (en) 2016-04-20

Family

ID=54193691

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13787577.9A Withdrawn EP2847175A4 (en) 2012-05-08 2013-02-03 Compositions and methods for suppression of carbonic anhydrase activity

Country Status (7)

Country Link
EP (1) EP2847175A4 (en)
JP (1) JP2015520748A (en)
CN (1) CN104364241A (en)
AU (1) AU2013257715B2 (en)
CA (1) CA2872978A1 (en)
SG (1) SG11201407317SA (en)
WO (1) WO2013167994A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379589A (en) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 Prodrugs of anti-platelet agents
CA2873018A1 (en) * 2012-07-03 2014-01-09 Cellixbio Private Limited Compositions and methods for the treatment of moderate to severe pain
CA3008111C (en) * 2014-02-03 2019-09-24 Eidgenoessische Technische Hochschule Zurich Low molecular weight drug conjugates for binding to carbonic anhydrase ix
WO2018211474A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
CN108969521A (en) * 2017-05-31 2018-12-11 邱正廸 The purposes of acetazolamide treatment cerebral hemorrhage
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014642A2 (en) * 1979-02-02 1980-08-20 Merck & Co. Inc. Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure
WO1992005786A1 (en) * 1990-09-28 1992-04-16 Merck & Co., Inc. Ibuprofen-diuretic combinations
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) * 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
US5157044A (en) * 1983-02-04 1992-10-20 University Of Iowa Research Foundation Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors
US5104887A (en) * 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
US5242937A (en) * 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
GB0821537D0 (en) * 2008-11-25 2008-12-31 Union Life Sciences Ltd Therapeutic target
WO2010147666A1 (en) * 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
CN101921245B (en) * 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 Sulfonamides compound for inhibiting carbonic anhydrase II and synthesis method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014642A2 (en) * 1979-02-02 1980-08-20 Merck & Co. Inc. Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure
WO1992005786A1 (en) * 1990-09-28 1992-04-16 Merck & Co., Inc. Ibuprofen-diuretic combinations
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGRAWAL V K ET AL: "QSAR study on topically acting sulfonamides incorporating GABA moieties: A molecular connectivity approach", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 7, 1 April 2006 (2006-04-01), pages 2044 - 2051, XP027966394, ISSN: 0960-894X, [retrieved on 20060401] *
ILIES M ET AL: "Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 8, no. 8, 1 August 2000 (2000-08-01), pages 2145 - 2155, XP027414362, ISSN: 0968-0896, [retrieved on 20000801] *
JENNIFFER I. ARENAS-GARCÍA ET AL: "Modification of the Supramolecular Hydrogen-Bonding Patterns of Acetazolamide in the Presence of Different Cocrystal Formers: 3:1, 2:1, 1:1, and 1:2 Cocrystals from Screening with the Structural Isomers of Hydroxybenzoic Acids, Aminobenzoic Acids, Hydroxybenzamides, Aminobenzamides, Nicotinic Acids,", CRYSTAL GROWTH & DESIGN., vol. 12rge, no. 2, 1 February 2012 (2012-02-01), US, pages 811 - 824, XP055255392, ISSN: 1528-7483, DOI: 10.1021/cg201140g *
LOFTSSON T ET AL: "The effect of water-soluble polymers on the aqueous solubility and complexing abilities of beta-cyclodextrin", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 163, no. 1-2, 1 January 1998 (1998-01-01), pages 115 - 121, XP003003295, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(97)00371-2 *
See also references of WO2013167994A1 *

Also Published As

Publication number Publication date
CA2872978A1 (en) 2013-11-14
AU2013257715B2 (en) 2016-05-05
WO2013167994A1 (en) 2013-11-14
SG11201407317SA (en) 2014-12-30
JP2015520748A (en) 2015-07-23
EP2847175A1 (en) 2015-03-18
AU2013257715A1 (en) 2014-11-27
CN104364241A (en) 2015-02-18

Similar Documents

Publication Publication Date Title
HK1251246A1 (en) Methods and compositions for desulfurization of compositions
ZA201508059B (en) Compositions and methods of use of phorbol esters
EP2836224A4 (en) Compositions of microbiota and methods related thereto
IL233476B (en) Carbamate compounds and methods of making and using same
EP2776567A4 (en) Compositions and methods for treatment of cytomegalovirus
HK1193837A1 (en) Polyurea compositions and methods of use
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2675471A4 (en) Hsa-related compositions and methods of use
EP2836218A4 (en) Prebiotic compositions and methods of use
EP2834322A4 (en) Biochar compositions and methods of use thereof
EP2672820A4 (en) Mannoside compounds and methods of use thereof
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
EP2847175A4 (en) Compositions and methods for suppression of carbonic anhydrase activity
EP2748190A4 (en) Wnt compositions and therapeutic uses of such compositions
EP2667889A4 (en) Wnt compositions and methods of use thereof
IL227924A0 (en) Compositions and methods of use for determination of he4a
EP2906041A4 (en) Compositions and methods of use of an inappetance-controlling compound
EP2755668A4 (en) Hyr1-derived compositions and methods of treatment using same
EP2753337A4 (en) Compositions including beta-glucans and methods of use
EP2809337A4 (en) ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP2859071A4 (en) Chemical compositions and methods of using same
HK1212998A1 (en) Ron compositions and methods of use thereof ron
EP2841164A4 (en) Dermal-appropriate compositions and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 285/135 20060101AFI20151006BHEP

Ipc: A61P 27/06 20060101ALI20151006BHEP

Ipc: A61K 31/433 20060101ALI20151006BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160322

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 285/135 20060101AFI20160316BHEP

Ipc: A61K 31/433 20060101ALI20160316BHEP

Ipc: A61P 27/06 20060101ALI20160316BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160511